Genmab A/S (GMAB) to Release Quarterly Earnings on Tuesday

Genmab A/S (NASDAQ:GMAB) is expected to post its Q4 2025 results before the market opens on Tuesday, February 17th. Analysts expect Genmab A/S to post earnings of $0.44 per share and revenue of $1.0560 billion for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, February 17, 2026 at 12:00 PM ET.

Genmab A/S Stock Up 1.5%

Shares of GMAB stock opened at $30.03 on Monday. The firm has a 50 day moving average of $32.35 and a 200-day moving average of $29.76. The company has a market cap of $19.29 billion, a price-to-earnings ratio of 12.78, a price-to-earnings-growth ratio of 17.63 and a beta of 0.90. Genmab A/S has a 52 week low of $17.24 and a 52 week high of $35.43.

Institutional Investors Weigh In On Genmab A/S

Several institutional investors and hedge funds have recently added to or reduced their stakes in GMAB. Kestra Advisory Services LLC purchased a new position in shares of Genmab A/S in the 4th quarter worth approximately $96,000. CANADA LIFE ASSURANCE Co increased its position in shares of Genmab A/S by 43.4% during the fourth quarter. CANADA LIFE ASSURANCE Co now owns 4,522 shares of the company’s stock valued at $139,000 after acquiring an additional 1,369 shares during the last quarter. Stifel Financial Corp lifted its holdings in Genmab A/S by 78.1% during the fourth quarter. Stifel Financial Corp now owns 39,931 shares of the company’s stock worth $1,230,000 after acquiring an additional 17,510 shares during the period. Hudson Bay Capital Management LP boosted its position in Genmab A/S by 22.6% in the fourth quarter. Hudson Bay Capital Management LP now owns 325,000 shares of the company’s stock worth $10,010,000 after purchasing an additional 60,000 shares during the last quarter. Finally, Smartleaf Asset Management LLC boosted its position in Genmab A/S by 9.8% in the fourth quarter. Smartleaf Asset Management LLC now owns 7,904 shares of the company’s stock worth $249,000 after purchasing an additional 706 shares during the last quarter. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Analyst Upgrades and Downgrades

GMAB has been the subject of a number of research reports. Wall Street Zen cut shares of Genmab A/S from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. Zacks Research cut shares of Genmab A/S from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 31st. Johnson Rice restated a “buy” rating on shares of Genmab A/S in a research note on Monday, October 27th. Truist Financial reaffirmed a “buy” rating and set a $48.00 price target (down from $49.00) on shares of Genmab A/S in a research note on Thursday, November 6th. Finally, HC Wainwright reiterated a “buy” rating and issued a $39.00 price target on shares of Genmab A/S in a report on Wednesday, January 28th. Five investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Genmab A/S has a consensus rating of “Moderate Buy” and an average price target of $43.33.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.